Orchestra Therapeutics, Inc., an immuno-pharmaceutical company, focuses on the development of various products to treat autoimmune and infectious diseases. It offers NeuroVax, an immune-based therapeutic product, which is based on T-cell receptor peptide technology for the treatment of multiple sclerosis. NeuroVax is in Phase II clinical trails. The company, formerly known as The Immune Response Corporation, was founded in 1986 and changed its name to Orchestra Therapeutics, Inc. in April 2007. Orchestra Therapeutics, Inc. is headquartered in Carlsbad, California. On October 13, 2008, Orchestra Therapeutics, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Southern District of California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for OCHT